Drug, across the briefings
Bevacizumab across 10 cancers
Bevacizumab appears in 10 of the briefings; its FDA label names 7 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Cervical cancer | label names disease | — | — | |
| Colorectal cancer | label names disease | — | — | |
| Glioblastoma | label names disease | — | — | |
| Hepatocellular carcinoma | label names disease | on VEGFA | 163 | 90 |
| Kidney cancer | label names disease | — | — | |
| Lung cancer | label names disease | — | — | |
| Ovarian cancer | label names disease | — | — | |
| Mesothelioma | on VEGFA | 15 | 5 | |
| Nasopharyngeal carcinoma | on VEGFA | 13 | 5 | |
| Osteosarcoma | on VEGFA | 3 | 1 |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.